Ignite Creation Date:
2024-05-05 @ 5:20 PM
Last Modification Date:
2024-10-26 @ 9:30 AM
Study NCT ID:
NCT00430898
Status:
COMPLETED
Last Update Posted:
2008-12-18
First Post:
2007-01-31
Brief Title:
Basiliximab in Moderate to Severe Ulcerative Colitis
Sponsor:
Cerimon Pharmaceuticals
Organization:
Cerimon Pharmaceuticals
Study Overview
Official Title:
A Randomized Double-Blind Placebo-Controlled Evaluation of the Safety Efficacy and Pharmacokinetics of Multiple Doses of Basiliximab With Concomitant Corticosteroids in Steroid-Refractory Ulcerative Colitis
Status:
COMPLETED
Status Verified Date:
2008-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to assess the safety effectiveness and pharmacokinetics of two levels of intravenous basiliximab in ulcerative colitis compared to placebo
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None